199 related articles for article (PubMed ID: 27479182)
21. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
22. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the antiapoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) and the stimulation of its message by gonadotropins in the rat ovary.
Leo CP; Hsu SY; Chun SY; Bae HW; Hsueh AJ
Endocrinology; 1999 Dec; 140(12):5469-77. PubMed ID: 10579309
[TBL] [Abstract][Full Text] [Related]
24. Mcl-1 is a key regulator of the ovarian reserve.
Omari S; Waters M; Naranian T; Kim K; Perumalsamy AL; Chi M; Greenblatt E; Moley KH; Opferman JT; Jurisicova A
Cell Death Dis; 2015 May; 6(5):e1755. PubMed ID: 25950485
[TBL] [Abstract][Full Text] [Related]
25. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
27. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases.
Agarwal B; Naresh KN
Am J Hematol; 2002 Aug; 70(4):278-82. PubMed ID: 12210808
[TBL] [Abstract][Full Text] [Related]
29. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Montraveta A; Xargay-Torrent S; Rosich L; López-Guerra M; Roldán J; Rodríguez V; Lee-Vergés E; de Frías M; Campàs C; Campo E; Roué G; Colomer D
Oncotarget; 2015 Aug; 6(25):21159-72. PubMed ID: 26110568
[TBL] [Abstract][Full Text] [Related]
30. Innate Conformational Dynamics Drive Binding Specificity in Anti-Apoptotic Proteins Mcl-1 and Bcl-2.
Wolf E; Lento C; Pu J; Dickinson BC; Wilson DJ
Biochemistry; 2023 Jun; 62(11):1619-1630. PubMed ID: 37192192
[TBL] [Abstract][Full Text] [Related]
31. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
[TBL] [Abstract][Full Text] [Related]
32. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
33. BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.
Klanova M; Klener P
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290241
[TBL] [Abstract][Full Text] [Related]
34. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
35. Mcl-1 is a potential therapeutic target in multiple types of cancer.
Akgul C
Cell Mol Life Sci; 2009 Apr; 66(8):1326-36. PubMed ID: 19099185
[TBL] [Abstract][Full Text] [Related]
36. Anti-apoptotic BCL-2 family members in development.
Opferman JT; Kothari A
Cell Death Differ; 2018 Jan; 25(1):37-45. PubMed ID: 29099482
[TBL] [Abstract][Full Text] [Related]
37. Delving deeper: MCL-1's contributions to normal and cancer biology.
Perciavalle RM; Opferman JT
Trends Cell Biol; 2013 Jan; 23(1):22-9. PubMed ID: 23026029
[TBL] [Abstract][Full Text] [Related]
38. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy.
Kelly PN; Strasser A
Cell Death Differ; 2011 Sep; 18(9):1414-24. PubMed ID: 21415859
[TBL] [Abstract][Full Text] [Related]
39. Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1.
Luptak J; Bista M; Fisher D; Flavell L; Gao N; Wickson K; Kazmirski SL; Howard T; Rawlins PB; Hargreaves D
Acta Crystallogr D Struct Biol; 2019 Nov; 75(Pt 11):1003-1014. PubMed ID: 31692474
[TBL] [Abstract][Full Text] [Related]
40. bcl-2: antidote for cell death.
Tsujimoto Y
Prog Mol Subcell Biol; 1996; 16():72-86. PubMed ID: 8822793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
